Comprehensive Cancer Center Munich (CCCM)
1 clinical trials · Sponsor
◉ Watch Comprehensive Cancer Center Munich (CCCM)
| Record | Firm | Date |
|---|---|---|
| Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma (NCT06657157) | Comprehensive Cancer Center Munich (CCCM) | 2025-01-22 |
Track Comprehensive Cancer Center Munich (CCCM) automatically
Every clearance here is in the API, with alerts when new ones post.